Ascendis Pharma A/S (ASND)
213.19
+7.38
(+3.59%)
USD |
NASDAQ |
Jun 09, 16:00
213.19
0.00 (0.00%)
After-Hours: 17:52
Ascendis Pharma SG&A Expense (Quarterly) : 169.91M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Evaxion AS | 1.527M |
| DBV Technologies SA | 15.36M |
| Genmab A/S | 166.61M |
| Cellectis SA | 5.610M |
| Akari Therapeutics Plc | 2.165M |